Drug-Induced Eosinophilia
EEosinophilia can be caused by various reasons, including taking certain medications, in which case it is called drug-induced. The relevance of drug-induced eosinophilia issue is due to the serious consequences associated with this condition, in particular eosinophilia-myalgia, DRESS-syndrome (Drug...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2019-12-01
|
| Series: | Безопасность и риск фармакотерапии |
| Subjects: | |
| Online Access: | https://www.risksafety.ru/jour/article/view/156 |
| _version_ | 1797224593653497856 |
|---|---|
| author | O. D. Ostroumova E. Yu. Shahova A. I. Kochetkov |
| author_facet | O. D. Ostroumova E. Yu. Shahova A. I. Kochetkov |
| author_sort | O. D. Ostroumova |
| collection | DOAJ |
| description | EEosinophilia can be caused by various reasons, including taking certain medications, in which case it is called drug-induced. The relevance of drug-induced eosinophilia issue is due to the serious consequences associated with this condition, in particular eosinophilia-myalgia, DRESS-syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms), heart damage and multisystem manifestations which can be fatal. Objective of this review is data analysis and systematization on the prevalence and risk factors for the drug-induced eosinophilia development, as well as a synthesis of existing methods for the prevention and treatment of this condition. Most often, drug-induced eosinophilia develops while taking certain antibiotics, sulfonamides, anti-malarial, anti-leprosy, anticonvulsant, non-steroidal anti-inflammatory drugs. The prevalence of drug-induced eosinophilia varies with the use of different drugs. This pathological condition occurs with the same frequency in both men and women of any age. Risk factors include the presence of several clonal hematological pathologies, non-hematological disorders (allergic and atopic diseases), infections (especially parasitic), tumors, as well as concomitant use of ≥2 of the above-mentioned drugs. The main way to prevent drug-induced eosinophilia is to refuse to use and/or replace the drug with another drug that does not have this side effect, provided the patient has clinical symptoms associated with eosinophilia. A symptomatic eosinophilia does not require the discontinuation of ongoing drug therapy. The presence of clinical symptoms associated with eosinophilia dictates the need for discontinuation of the drug, but if this is not possible, the treatment is continued with careful monitoring of the clinical picture and hematological parameters. |
| first_indexed | 2024-03-08T22:27:11Z |
| format | Article |
| id | doaj.art-3231db3a4613427dbc4bd1132ce050ea |
| institution | Directory Open Access Journal |
| issn | 2312-7821 2619-1164 |
| language | Russian |
| last_indexed | 2024-04-24T13:55:35Z |
| publishDate | 2019-12-01 |
| publisher | Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» |
| record_format | Article |
| series | Безопасность и риск фармакотерапии |
| spelling | doaj.art-3231db3a4613427dbc4bd1132ce050ea2024-04-03T17:56:36ZrusMinistry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Безопасность и риск фармакотерапии2312-78212619-11642019-12-017417618910.30895/2312-7821-2019-7-4-176-189147Drug-Induced EosinophiliaO. D. Ostroumova0E. Yu. Shahova1A. I. Kochetkov2Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Russian Clinical and Research Center of Gerontology; A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian FederationA.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian FederationPirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Russian Clinical and Research Center of GerontologyEEosinophilia can be caused by various reasons, including taking certain medications, in which case it is called drug-induced. The relevance of drug-induced eosinophilia issue is due to the serious consequences associated with this condition, in particular eosinophilia-myalgia, DRESS-syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms), heart damage and multisystem manifestations which can be fatal. Objective of this review is data analysis and systematization on the prevalence and risk factors for the drug-induced eosinophilia development, as well as a synthesis of existing methods for the prevention and treatment of this condition. Most often, drug-induced eosinophilia develops while taking certain antibiotics, sulfonamides, anti-malarial, anti-leprosy, anticonvulsant, non-steroidal anti-inflammatory drugs. The prevalence of drug-induced eosinophilia varies with the use of different drugs. This pathological condition occurs with the same frequency in both men and women of any age. Risk factors include the presence of several clonal hematological pathologies, non-hematological disorders (allergic and atopic diseases), infections (especially parasitic), tumors, as well as concomitant use of ≥2 of the above-mentioned drugs. The main way to prevent drug-induced eosinophilia is to refuse to use and/or replace the drug with another drug that does not have this side effect, provided the patient has clinical symptoms associated with eosinophilia. A symptomatic eosinophilia does not require the discontinuation of ongoing drug therapy. The presence of clinical symptoms associated with eosinophilia dictates the need for discontinuation of the drug, but if this is not possible, the treatment is continued with careful monitoring of the clinical picture and hematological parameters.https://www.risksafety.ru/jour/article/view/156blood eosinophiliadrug-induced eosinophiliaаdverse drug reactionantibioticssulfanilamidesantimalarial drugsanti-seizure medicationsnonsteroidal anti-inflammatory drugs |
| spellingShingle | O. D. Ostroumova E. Yu. Shahova A. I. Kochetkov Drug-Induced Eosinophilia Безопасность и риск фармакотерапии blood eosinophilia drug-induced eosinophilia аdverse drug reaction antibiotics sulfanilamides antimalarial drugs anti-seizure medications nonsteroidal anti-inflammatory drugs |
| title | Drug-Induced Eosinophilia |
| title_full | Drug-Induced Eosinophilia |
| title_fullStr | Drug-Induced Eosinophilia |
| title_full_unstemmed | Drug-Induced Eosinophilia |
| title_short | Drug-Induced Eosinophilia |
| title_sort | drug induced eosinophilia |
| topic | blood eosinophilia drug-induced eosinophilia аdverse drug reaction antibiotics sulfanilamides antimalarial drugs anti-seizure medications nonsteroidal anti-inflammatory drugs |
| url | https://www.risksafety.ru/jour/article/view/156 |
| work_keys_str_mv | AT odostroumova druginducedeosinophilia AT eyushahova druginducedeosinophilia AT aikochetkov druginducedeosinophilia |